Many trials in breast cancer have investigated various aspects of locoregional and systemic treatments. Combination of the results of these trials in a meticulous meta-analysis, as has been done several times by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), fi lls the gaps in evidence and knowledge by conclusively showing signifi cant trends and diff erences.
Following publication of the eff ect of radiotherapy after breast-conserving therapy, 1 the EBCTCG now presents results for postmastectomy radiotherapy in The Lancet. 2 The central issue is the role of postmastectomy radiotherapy in patients with one to three involved axillary lymph nodes, which is currently a matter of debate in many countries. 3 Whereas the earlier results were essentially confi rmed in this report, 1,4 we get more insight into the eff ect of the extent of lymph-node involvement, the number of examined axillary lymph nodes, and the use of adjuvant systemic therapy. Overall, postmastectomy radiotherapy improves locoregional disease-free survival, overall disease-free survival, and breast-cancer-specifi c survival for all patients with involvement of axillary lymph nodes, irrespective of the number of involved lymph nodes and of administration of adjuvant systemic therapy. This improvement is not only statistically signifi cant, but also clinically relevant.
The proportional reductions in rates of recurrence and mortality were independent of the administration of systemic therapy. Whether this fi nding also applies to patients treated with more contemporary regimens remains to be seen. We need to continue evaluating results of the contemporary multidisciplinary approach in breast cancer to better understand the complex interaction between respective contributions of systemic and locoregional treatments to the fi nal outcome, including survival and toxic eff ects. As Punglia and colleagues 5 pointed out, the contribution of improved locoregional control to survival depends on the eff ectiveness of systemic treatment. Punglia and colleagues' bell-shaped curve, 5 however, misses the component of metastatic risk of the primary tumour. Combining both, the infl uence of both the eff ectiveness of systemic therapy and metastatic risk of the primary tumour can be used to estimate the Patients in the left part of the slope have high-risk disease without eff ective systemic therapy and are not expected to benefi t from improving locoregional treatments. For patients in the right part of the slope, treatment deintensifi cation (surgery, radiation, or systemic therapy) might be appropriate. The middle group will represent most past and current patients with breast cancer, for whom an optimum multidisciplinary approach results in the greatest benefi t. contribution of improved locoregional treatment to the fi nal outcome (fi gure). For many patients, improvement of systemic therapy will decrease the risk of death due to distant metastasis, after which the importance of optimised locoregional control-which will already be better after systemic treatment-will, relatively, contribute more to survival.
As the EBCTCG outlines, 2 interpretation of the fi ndings should take into account the decreased locoregional recurrence rates during recent decades owing to improvements in diagnostic and therapeutic procedures. However, the complex interaction between locoregional and distant recurrences as a fi rst event (illustrated in the appendix of the Article) clearly shows that the two types of event should not be considered individually as separate events but taken together. Improvements in locoregional treatments will only directly aff ect the development and further spread of subclinical locoregional tumour deposits. Moreover, we should realise that the incidence of locoregional recurrences at diagnosis of distant metastasis is underestimated because of a lack of relevance of its detection and no routine accurate diagnosis, especially for regional recurrences, making the latter a poor endpoint for trials evaluating locoregional treatments.
6 Also of note in this respect is the fi nding that the one in four rule from earlier EBCTCG meta-analyses (ie, for every four recurrences avoided about one life was saved) cannot be generalised to all patient groups; in the present analysis, about one breast cancer death at 20 years was avoided for every 1·5 recurrences avoided at 10 years.
1,2,4
This meta-analysis also shows the importance of the extent of axillary surgery, with a greater benefi t of postmastectomy radiotherapy for patients who had axillary sampling as compared with a complete axillary dissection, even in node-negative patients. However, it should be noted that the sentinel lymph-node procedure was not yet used in these trials, so care should be taken not to extrapolate the results to this now common procedure. Notwithstanding this limitation, the fi ndings warn against the current trend of omission of further regional treatment after a positive sentinel lymph node on the basis of data for regional recurrences and short-term follow-up. 7 As reported before, radiotherapy can increase the rate of deaths not related to breast cancer, mainly by inducing cardiac diseases and secondary cancers. [8] [9] [10] This outcome lowers the benefi t of radiotherapy on breast cancer mortality after longer follow-up, as shown in the appendix of the Article. However, modern radiotherapy techniques allow the non-intended dose to organs at risk to be decreased, while at the same time improving coverage of the target volumes. 11, 12 Therefore, continued follow-up is needed to understand fully the ultimate infl uence of radiotherapy on breast-cancer-related mortality and on late toxic eff ects.
The results of this EBCTCG meta-analysis clearly confi rm that postmastectomy radiotherapy should be considered equally for patients with one to three involved axillary lymph nodes as it should be for patients with four or more aff ected axillary lymph nodes. The same considerations concerning regional radiotherapy also seem to be valid for patients treated with breast-conserving therapy.
1,2 Here, the addition of regional radiotherapy to whole breast irradiation adds less to the burden of treatment to the patient, on the condition that long-term toxic eff ects can be avoided with modern radiotherapy techniques.
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Department of Radiation Oncology, Institute Verbeeten, Tilburg, LA 5000, Netherlands poortmans.ph@bvi.nl In The Lancet, Nita Bhandari and colleagues' study 1 about the effi cacy of the new 116E rotavirus vaccine in Indian infants off ers an opportunity to address the substantial lag in translation of scientifi c progress for the benefi t of the world's most vulnerable population.
Vaccination is considered to be second only to access to potable water in its potential cost-eff ectiveness as a health-care strategy for improving child health. Most childhood deaths from vaccine-preventable diseases, such as Haemophilus infl uenzae type b (Hib), Streptococcus pneumoniae, and rotavirus, happen in low-income countries. 2 However, introduction of lifesaving vaccines, such as Hib conjugate vaccine, into national immunisation programmes in low-income countries has lagged by as much as 20 years behind implementation in high-income settings.
3 Of the many factors responsible, constraints around vaccine aff ordability and supply are key.
In the past decade, progress has been made in reducing the delay in the introduction of new childhood vaccines (eg, those against pneumococcus and rotavirus) into immunisation programmes between developed and developing countries. This progress is largely attributable to international donor funding coordinated under the auspices of the GAVI Alliance, which among other things provides cofi nancing for vaccine procurement at discounted prices negotiated with manufacturers for countries that meet an income threshold for eligibility (presently a gross national income per person of ≤US$1550). However, the sustainability of the GAVI process, in which countries are expected to take over ownership of funding for vaccine procurement once their gross national income per person exceeds GAVI's eligibility threshold, remains a concern. One way to address this challenge is to explore approaches to development of low-cost, safe, and eff ective vaccines that are aff ordable for low-income countries.
Within this framework, the development of 116E rotavirus vaccine provides a model of a successful tripartite alliance between donors, governmental institutions, and a willing private sector, to ensure that vaccines are developed at aff ordable prices. Clinical development of the 116E vaccine was undertaken by an emerging Indian vaccine manufacturer-Bharat Biotech-with full partnership and partial fi nancial support from the Department of Biotechnology of the Indian Government, and with technical and fi nancial support from a consortium of international partners and donors. In lieu of public sector support to off set some of the research and development costs, the manufacturer has committed to making the vaccine available to the public sector at less than $1 per dose for a three-dose series. This regime is in comparison to the discounted cost, $2·50 per dose for a two-dose series and $3·50 per dose for a three-dose series, of two other licensed rotavirus vaccines that GAVI pays for countries that procure vaccine through UNICEF. 4 Benefi ciary lowincome countries contribute $0·40 in co-fi nancing for a full series of either vaccine.
